Summary
This review concerns the clinical impact of treating hyperlipidemia. The U.S. Lipid Research Clinics Coronary Primary Prevention Trial, the Helsinki Heart Study, and the Olso Primary Prevention Trial all consistently showed that intensive and long-term (5–7 years) lipidlowering treatment is successful in reducing the incidence of fatal and nonfatal myocardial infarction. Secondary prevention trials (Coronary Drug Project, and the Stockholm Ischaemic Heart Disease Secondary Prevention Study) have overall confirmed this result. Assessment of progression/ regression of atherosclerosis by invasive or noninvasive methods has shown that an important mechanism underlying the reduction of coronary events with long-term lipidlowering treatment is that involving stabilization or regression of arterial lesions. An, additional advantage from lipidlowering treatment might come from useful hemodynamic changes, occurring shortly after the start of an intensive cholesterol-lowering treatment with low-density lipoprotein apheresis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lipid Reserach Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results. I. Reduction in incidence of coronary heart disease.JAMA 1984;251:351–364.
Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors and incidence of coronary heart disease.N Engl J Med 1987;317:1237–1245.
Hjermann I, Byre KV, Holme I, Leren P, Effect of diet and smoking intervention on the incidence of coronary heart disease: Report from the Oslo Study Group of a randomized trial in healthy men.Lancet 1981;2:1303–1310.
Holme I, Hjerman I, Helgeland A, Leren P. The Oslo Study: Diet and antismoking advice. Additional results from a 5-year primary preventive trial in middle-aged men.Prec Med 1985;14:279–292.
Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease.JAMA 1975;231:360–381.
Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in coronary; drug project patients: Long term benefit with niacin.J Am Coll Cardiol 1986;8:1245–1255.
Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid.Acta Med Scand 1988;223:405–418.
Brensike JF, Levy RI, Kelsey SF, et al. Effects of therapy with cholestyramine on progression of coronary heart arteriosclerosis: Results of the NHLBI Type II Coronary Intervention Study.Circulation 1984;69:313–324.
Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts.JAMA 1987;257:3233–3240.
Duffield GM, Lewis B, Miller NE, et al. Treatment of hyperlipidaemia retards progression of symptomatic femoral atherosclerosis. A randomised controlled trial.Lancet 1983; 2:639–642.
Rubba P, Iannuzzi A, Postiglione A, et al. Haemodynamic changes in the peripheral circulation after repeat LDL-apheresis in familial hypercholesterolemia.Circulation 1990;81:610–616.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mancini, M., Pauciullo, P. Clinical Relevance of hyperlipidemia. Cardiovasc Drug Ther 4, 1385–1388 (1990). https://doi.org/10.1007/BF02018266
Issue Date:
DOI: https://doi.org/10.1007/BF02018266